Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.55 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970278 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL30219250 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL8382466 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL31378334 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL19373 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL4726036 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL19374 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL29706692 | 0.97 | FOLH1 (0.51) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL30288867 | 0.97 | FOLH1 (0.51) | FOLH1NAALAD2RIMKLAKMT2AALOX15 | |
| SCHEMBL29636521 | 0.97 | FOLH1 (0.51) | FOLH1NAALAD2RIMKLAKMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20250263437-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| EP-4583982-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | Cardiff Oncology, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| EP-4565572-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119997977-A | Cancer treatment using MTDP inhibitors and PLK1 inhibitors | 凯帝夫肿瘤科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2025096879-A1 | BREAST CANCER TREATMENT USING CELL CYCLE INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| WO-2025034802-A2 | AGENTS FOR DELIVERY OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2025-02-13 | — | — | WO | claimed |
| WO-2025034764-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Life Technologies Corporation (US) | 2025-02-13 | — | — | WO | claimed |
| US-20230127824-A1 | IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED RADIOPACITY | BOSTON SCIENTIFIC SCIMED INC. (US) | 2023-04-27 | — | — | US | claimed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | claimed |
| CN-114805489-A | Polypeptide for repairing skin injury or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022148289-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | 四川好医生攀西药业有限责任公司 | 2022-07-14 | — | — | WO | claimed |
| WO-2022140565-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES (US) | 2022-06-30 | — | — | WO | claimed |
| US-20160282351-A1 | SALIVARY BIOMARKERS FOR CANCERS, METHODS AND DEVICES FOR ASSAYING THE SAME, AND METHODS FOR DETERMINING SALIVARY BIOMARKERS FOR CANCERS | SALIVATECH CO., LTD. (JP) | 2016-09-29 | — | — | US | claimed |
| EP-3064940-A1 | SALIVARY BIOMARKER FOR CANCER, METHOD AND DEVICE FOR ASSAYING SAME, AND METHOD FOR DETERMINING SALIVARY BIOMARKER FOR CANCER | Salivatech Co., Ltd. (JP) | 2016-09-07 | — | — | EP | claimed |
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| WO-2012010851-A1 | CAPILLARY ELECTROPHORESIS OF CARBOHYDRATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-01-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK4, PLK2 | FOLH1 2365/4885NAALAD2 2158/4885RIMKLA 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.